PTX-200 and Carboplatin in Ovarian Cancer
A Phase IA/IB Trial of PTX-200 and Carboplatin in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Sponsor: Prescient Therapeutics, Ltd.
Terminated
Enrollment stopped prior to Phase 1b, change in strategic focus
A PHASE1/PHASE2 clinical study on Ovarian Cancer, this trial is terminated or withdrawn. The trial is conducted by Prescient Therapeutics, Ltd. and has accumulated 12 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Apr 2020 — Oct 2020 [monthly]
Terminated PHASE1_PHASE2
Status: Active Not Recruiting → Terminated
▶ Show 7 earlier versions
-
Feb 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2019 — Feb 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2018 — Apr 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Feb 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Prescient Therapeutics, Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .